Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study
Bruno Lioure, Marie C Béné, Arnaud Pigneux, Anne Huynh, Patrice Chevallier, Nathalie Fegueux, Didier Blaise, Brigitte Witz, Martine Delain, Jérôme Cornillon, Isabelle Luquet, Odile Blanchet, Pascale Cornillet-Lefebvre, Martin Carré, Mathilde Hunault, Fabrice Larosa, Thierry Lamy, Edouard Randriamalala, Mario Ojeda-Uribe, Christian Berthou, Luc Fornecker, Jean-Luc Harousseau, Didier Bouscary, Norbert Ifrah, Jean-Yves Cahn, GOELAMS, Bruno Lioure, Marie C Béné, Arnaud Pigneux, Anne Huynh, Patrice Chevallier, Nathalie Fegueux, Didier Blaise, Brigitte Witz, Martine Delain, Jérôme Cornillon, Isabelle Luquet, Odile Blanchet, Pascale Cornillet-Lefebvre, Martin Carré, Mathilde Hunault, Fabrice Larosa, Thierry Lamy, Edouard Randriamalala, Mario Ojeda-Uribe, Christian Berthou, Luc Fornecker, Jean-Luc Harousseau, Didier Bouscary, Norbert Ifrah, Jean-Yves Cahn, GOELAMS
Abstract
The LAM2001 phase 3 trial, involving 832 patients with acute myeloid leukemia (AML; median: 46 years) proposed HLA-identical sibling allograft HSCT for all patients with an identified donor. The trial compared reduced-intensity conditioning (RIC) for patients older than 50 years of age (N = 47) and myeloablative conditioning for younger patients (N = 117). BM HSCT was performed in the younger patients, while the older ones received a consolidation course, followed by peripheral blood allo-HSCT using RIC. The incidence of grade II-IV acute GVHD, was 51.9% (95% confidence interval [CI]: 42.1-61.8) and 11.3% (1.6-21.2) after myeloablative or RIC, respectively (P < .0001) and that of chronic GVHD 45.8% (95% CI: 34.8-56.7) and 41.7% (24.7-58.6; NS). Cumulative incidence of nonrelapse mortality at 108 months was 15.8% (95% CI: 9.8-23.2) for myeloablative, and 6.5% (0.2-16.2) for RIC (NS). CI of relapse at 108 months was 21.7% (95% CI: 13.9-28.6) and 28.6% (16.5-43.4; NS). Overall survival at 108 months was 63.4% (95% CI: 54.6-72.2) and 65.8% (52.2-72.2), respectively, after myeloablative or RIC (NS). RIC peripheral blood stem cell allo-HSCT is prospectively feasible for patients between the ages of 51 and 60 years without excess of relapse or nonrelapse mortality, and compares favorably with myeloablative marrow allo-HSCT proposed to younger patients.
Trial registration: ClinicalTrials.gov NCT01015196.
Source: PubMed